Role of Perioperative Dexmedetomidine on Intraoperative Hemodynamics and Neuro-endocrine Response in Patients Undergoing Robot-Assisted Gynecological Surgery
The aim of this study is to evaluate role of perioperative Dexmedetomidine on intraoperative hemodynamics and neuro-endocrine response in patients undergoing Robot-Assisted gynecological surgery.
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Description détaillée
The aim of this study is to evaluate role of perioperative Dexmedetomidine on intraoperative hemodynamics and neuro-endocrine response in patients undergoing Robot-Assisted gynecological surgery.
-
Pre-operative settings:
Preoperative evaluation of full medical history, laboratory investigations in form of complete blood count, blood sugar, liver function tests, kidney function tests, serum electrolytes and coagulation profile and for fulfilling inclusion criteria. Patients will be trained how to use visual analogue scale (VAS).
Patients will be divided into two groups:
Group D :(n = 25) will receive (1 μg/kg) of dexmedetomidine as a loading intravenously for 10 min before anesthesia induction and will be continuously infused at 0.2 μg/kg/h intraoperatively.
Group P: (n = 25) will receive The same volume of normal saline in the same manner to group D.
-
Intraoperative Settings:
All patients will receive the standard technique of general anesthesia by the supervisors of the research. Two intravenous wide pore accesses will be secured, one for routine fluids and the other exclusively for Dex. All the patients will receive pantoprazole 40 mg and Ondansetron 4mg intravenously 15 min before induction and Loading dose of Dex infusion 1 mcg/kg will be started and continued for 10 minutes for group D and Normal saline with the same volume will be given to group P in the same manner.
ECG, non-invasive blood pressure and pulse oximeter will be established upon the patient's arrival in the operating room. Induction of anesthesia in both groups will be done by intravenous 1-2 mg/kg propofol, 1mic/kg fentanyl and 0.5 mg/kg atracurium.
Maintenance will be achieved with appropriate sized cuffed endotracheal tube passed orally, and the placement will be confirmed with auscultation and end-tidal carbon dioxide (EtCO2) reading. Anesthesia will be maintained with air and oxygen mixture (60:40), and isoflurane, using a closed circuit , top-up doses of atracurium , and the rate of Dex infusion will be changed to a maintenance infusion of 0.2 mcg/kg/h for group D and the same with normal saline for group P. End-tidal concentration of isoflurane will be monitored by measuring the average concentration and its total dosage through the infrared multi-gas analyzers. Vasopressor response to laryngoscopy and intubation will be documented by noting HR and BP. The lungs will be ventilated by maintaining a tidal volume of 6-8 ml/kg, and a respiratory rate to keep ETCO2 at 35-40 mmHg with continuous monitoring.
Intra-operative bradycardia (pulse rate <50) will be treated with atropine 0.6 mg.
Intra-operative hypotension will be treated with intravenous crystalloids and by reducing the isoflurane concentration and ephedrine. An increase in HR and/or mean arterial pressure (MAP) >20% from baseline values will be treated by 1 mcg/kg of intravenous fentanyl. If there will be no response within 5 min, the initial isoflurane concentration will be increased by 0.2% increment every 4 min up to a maximum of 1% end-tidal concentration. Any additional requirement of lapetalol or nitroglycerine to control BP will be noted Isoflurane inhalation will be stopped 10 min before the end of surgery and dexmedetomidine will be stopped at the end of skin incision closure. The total amount of fentanyl administered during each case will be also recorded.
Blood samples will be analyzed for blood Serum cortisol level, serum glucose and serum lactate.
Serum cortisol level preoperatively (baseline), just after incision, at 6 h after anesthesia induction, at 12 h after induction and at 24 h after induction.
Serum glucose level preoperatively (baseline), just after incision and at 6 h after anesthesia induction.
Serum lactate level preoperatively (baseline), just after incision, at 6 h after anesthesia induction and at 12 h after induction.
-
Hemodynamic monitoring:
Intraoperative monitoring was documented during the pre-induction, after the loading dose of Dex, at the induction of anesthesia, during laryngoscopy and intubation, and at pneumoperitoneum and then every 30 min till the end of surgery and continued during extubation and post operatively for 1 hr every 30 min.
-
Assessment of post-operative pain & sedation:
By the end of surgery, anesthesia will be discontinued and reversal will be given (when full muscle power regained) as neostigmine 0.05 mg/kg and atropine 0.02 mg/kg. Extubation will be done, and the patient will be transferred to the PACU.
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Phase
Phase
- Phase 4
Contacts et emplacements
Coordonnées de l'étude
Coordonnées de l'étude
- Nom: Tasneem Fathy Zahran, M.B.B.Ch., Master's Degree
- Numéro de téléphone: +20 1281946002
- E-mail: TasneemFathy@med.asu.edu.eg
Sauvegarde des contacts de l'étude
- Nom: Hala said Hassan, MD
- Numéro de téléphone: +201147784179
Lieux d'étude
-
-
Abbassia, Egypt
-
Cairo, Abbassia, Egypt, Egypte
- Recrutement
- Ain Shams University
-
Contact:
- Tasneem Fathy Zahran, M.B.B.Ch., Master's Degree
- Numéro de téléphone: +201281946002
- E-mail: TasneemFathy@med.asu.edu.eg
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Patients aged from 21-60 years.
- Patients ASA I or II undergoing elective Robot-Assisted gynecological surgery under general anesthesia.
Exclusion Criteria:
- Patient refusal.
- ASA III and ASA IV.
- A known history of allergy to the drugs used.
- Patients on chronic steroid therapy.
- Patient with cardiovascular disorder (Bradycardia, heart block, heart failure).
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Tripler
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: Group D (Dexmedetomidine)
Receives IV dexmedetomidine loading dose (1 μg/kg over 10 minutes before anesthesia induction) followed by a continuous infusion (0.2 μg/kg/h) until 15 minutes before the end of surgery. |
IV loading dose of 1 μg/kg over 10 min prior to induction, then maintenance infusion of 0.2 μg/kg/h until 15 min prior to surgery end. |
|
Comparateur placebo: Group P (Placebo)
Receives normal saline in the same volume and infusion rate schedule as Group D (loading dose over 10 minutes before induction, followed by continuous infusion). |
Equivalent volume of normal saline solution administered as an IV loading dose and continuous infusion matching the study drug timeline. |
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Serum Cortisol Level
Délai: Baseline (preoperatively), just after skin incision, and at 6 hours, 12 hours, and 24 hours after anesthesia induction.
|
Evaluation of the perioperative neuro-endocrine stress response by measuring blood serum cortisol levels. |
Baseline (preoperatively), just after skin incision, and at 6 hours, 12 hours, and 24 hours after anesthesia induction.
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Time to First Rescue Analgesia
Délai: Up to 24 hours postoperatively
|
The time interval between the completion of drug injection and the participant's first post-operative request for pain relief administered when Numerical Pain Distress Scale above 4 as • 0: No pain
|
Up to 24 hours postoperatively
|
|
Serum Glucose level
Délai: Serum glucose: Baseline, just after incision, and 6 hours post-induction.
|
Blood serum level of glucose to assess metabolic stress. |
Serum glucose: Baseline, just after incision, and 6 hours post-induction.
|
|
Numerical Pain Distress Scale (NPDS) Score
Délai: Upon recovery in PACU and throughout the first 24 hours postoperatively.
|
Self-reported pain intensity scored on an 11-point scale (0 = No pain to 10 = Unbearable pain). Higher number means high pain intensity. |
Upon recovery in PACU and throughout the first 24 hours postoperatively.
|
|
Ramsay Sedation Scale Score
Délai: Upon recovery in PACU and during the first 2 hours postoperatively.
|
Assessment of sedation level scored from 1 (anxious or restless) to 6 (no response to stimulus). |
Upon recovery in PACU and during the first 2 hours postoperatively.
|
|
Intraoperative Analgesic Consumption
Délai: Intraoperatively measured from induction till end of surgery.
|
Total intraoperative fentanyl consumption. |
Intraoperatively measured from induction till end of surgery.
|
|
Intraoperative Mean Arterial Pressure (MAP)
Délai: Recorded pre-induction, post-loading dose, at induction, during laryngoscopy/intubation, at pneumoperitoneum, every 15 minutes intraoperatively, at extubation, and every 30 minutes for 1 hour postoperatively.
|
Hemodynamic monitoring to assess stability and vasopressor/anticholinergic response. |
Recorded pre-induction, post-loading dose, at induction, during laryngoscopy/intubation, at pneumoperitoneum, every 15 minutes intraoperatively, at extubation, and every 30 minutes for 1 hour postoperatively.
|
|
Incidence of Side Effects and Complications
Délai: Up to 24 hours postoperatively.
|
Occurrence of postoperative nausea, vomiting, bradycardia, hypotension, or respiratory depression. It will be recorded as yes or No . |
Up to 24 hours postoperatively.
|
|
Lactate Level
Délai: Serum lactate: Baseline, just after incision, 6 hours, and 12 hours post-induction.
|
Blood serum lactate level to assess metabolic stress. |
Serum lactate: Baseline, just after incision, 6 hours, and 12 hours post-induction.
|
|
Postoperative Analgesic Consumption
Délai: through 24 hours postoperatively.
|
Total postoperative meperidine consumption. |
through 24 hours postoperatively.
|
|
Intraoperative Anesthetic Consumption
Délai: Intraoperatively measured from induction till end of surgery.
|
Total intraoperative consumption of isoflurane and average end-tidal concentration |
Intraoperatively measured from induction till end of surgery.
|
|
Intraoperative Heart Rate (HR)
Délai: Recorded pre-induction, post-loading dose, at induction, during laryngoscopy/intubation, at pneumoperitoneum, every 15 minutes intraoperatively, at extubation, and every 30 minutes for 1 hour postoperatively.
|
Hemodynamic monitoring to assess stability and vasopressor/anticholinergic response. |
Recorded pre-induction, post-loading dose, at induction, during laryngoscopy/intubation, at pneumoperitoneum, every 15 minutes intraoperatively, at extubation, and every 30 minutes for 1 hour postoperatively.
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Début de l'étude
Achèvement primaire (Estimé)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- FMASU MD328/2025
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Individual participant data will not be publicly shared in an open repository to protect participant privacy. Aggregate data and trial results will be published in a peer-reviewed journal upon study completion.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .